Exjade and Renal impairment - a phase IV clinical study of FDA data
Summary:
Renal impairment is reported as a side effect among people who take Exjade (deferasirox), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Neoral, and have Myelodysplastic syndrome.
The phase IV clinical study analyzes which people have Renal impairment when taking Exjade. It is created by eHealthMe based on reports of 29,418 people who have side effects when taking Exjade from the FDA, and is updated regularly.
What is Exjade?
Exjade has active ingredients of deferasirox. It is often used in iron overload. eHealthMe is studying from 29,456 Exjade users. Check the latest studies of Exjade.
What is Renal impairment?
Renal impairment (severely reduced kidney function) is found to be associated with 2,210 drugs and 2,471 conditions by eHealthMe. Check the latest studies of Renal impairment.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
29,418 people reported to have side effects when taking Exjade.
Among them, 598 people (2.03%) have Renal impairment.
Among these 598 people:
How long have people been on Exjade when they have Renal impairment? *
What is the gender of people who have Renal impairment when taking Exjade? *
What is the age of people who have Renal impairment when taking Exjade? *
What are other drugs people take besides Exjade? *
What are other side effects people have besides Renal impairment? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Exjade and have Renal impairment?
- Check whether Renal impairment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Exjade:
- Exjade (29,456 reports)
Renal impairment treatments and more:
- Renal impairment (99,633 reports)
How severe was Renal impairment and when was it recovered:
Expand to all the drugs that have ingredients of deferasirox:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Exjade:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Renal impairment:
- Renal impairment (2,210 drugs)
Browse all the conditions that are associated with Renal impairment:
- Renal impairment (2,471 conditions)
Related publications that referenced our studies
- Al-Hamdy RA, "Assessment of electrolytes and HbA1c in type 2 diabetic patients using metformin and evaluation of guidelines obedience regarding renal impairment", J.Thi-Qar Sci., 2015 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Al-Hamdy RA, "Assessment of electrolytes and HbA1c in type 2 diabetic patients using metformin and evaluation of guidelines obedience regarding renal impairment", J.Thi-Qar Sci., 2015 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on deferasirox (the active ingredients of Exjade) and Exjade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Immunodeficiency Disorders and Nephropathy Toxic - 4 seconds ago
- Enalapril Maleate And Hydrochlorothiazide vs. Crestor, side effect and effectiveness comparison - 7 seconds ago
- Hypercholesterolaemia Aggravated and Eye Disorder - 13 seconds ago
- Could Etoposide cause Thrombocytopenic Purpura? - 16 seconds ago
- Could Nitrofurantoin cause Pulmonary Hypertension? - 20 seconds ago
- Hot Flushes Aggravated and Stress And Anxiety - 21 seconds ago
- Herpes Zoster and Malaise - 32 seconds ago
- Drug interactions of Risperidone and Hydroxychloroquine Sulfate - 37 seconds ago
- Could Shark Cartilage cause Bone Density Decreased? - 50 seconds ago
- Could Ultravist cause Type I Hypersensitivity? - 51 seconds ago